Literature DB >> 11595258

Sustained attention and inhibition of cognitive interference in treated phenylketonuria: associations with concurrent and lifetime phenylalanine concentrations.

S C J Huijbregts1, L M J de Sonneville, R Licht, F J van Spronsen, P H Verkerk, J A Sergeant.   

Abstract

Fifty-seven 7-14-year-old early- and continuously treated phenylketonuria (PKU) patients and 65 matched controls performed a sustained attention task. PKU patients with plasma phenylalanine (phe) levels higher than 360 micromol/l at the time of testing exhibited, compared to controls, lower speed of information processing, a lower ability to inhibit task-induced cognitive interference, less consistent performance, and a stronger decrease of performance level over time. Patients with concurrent phe levels lower than 360 micromol/l did not differ from controls and were significantly better than patients with levels higher than 360 micromol/l. Strong relationships were found with task performance for phe levels during the pre-school years and between ages 5 and 7. These correlations were stronger than those between concurrent phe level and task performance. Significant multiple regression models were found with age accounting for the largest proportion of variance of tempo and tempo fluctuation, and lifetime phe levels (particularly phe level between ages 5 and 7) accounting for the largest proportion of variance of the relative number of inhibition errors and its increase over time. Phe level between ages 5 and 7 also contributed significantly to the variance of tempo and tempo fluctuation. Neuropsychological outcome was independent of IQ. The results indicate that strict dietary adherence during these periods is beneficial to attentional control later in life. We suggest that phe levels should be maintained under 360 micromol/l until approximately age 12, when development of attentional control approaches an adult level.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11595258     DOI: 10.1016/s0028-3932(01)00078-1

Source DB:  PubMed          Journal:  Neuropsychologia        ISSN: 0028-3932            Impact factor:   3.139


  36 in total

1.  Behavioural factors related to metabolic control in patients with phenylketonuria.

Authors:  M R Crone; F J van Spronsen; K Oudshoorn; J Bekhof; G van Rijn; P H Verkerk
Journal:  J Inherit Metab Dis       Date:  2005       Impact factor: 4.982

2.  Outcomes of phenylketonuria with relevance to follow-up.

Authors:  F J van Spronsen; A Bélanger-Quintana
Journal:  JIMD Rep       Date:  2011-06-22

3.  Tyrosine monitoring in children with early and continuously treated phenylketonuria: results of an international practice survey.

Authors:  Rachael Sharman; Karen A Sullivan; Ross McD Young; James J McGill
Journal:  J Inherit Metab Dis       Date:  2010-09-30       Impact factor: 4.982

4.  Cognitive functioning and psychiatric disorders in children with a metabolic disease.

Authors:  Annik Simons; François Eyskens; Ann De Groof; Ellen Van Diest; Dirk Deboutte; Robert Vermeiren
Journal:  Eur Child Adolesc Psychiatry       Date:  2006-03-10       Impact factor: 4.785

5.  Response monitoring in children with phenylketonuria.

Authors:  Gabriel C Araujo; Shawn E Christ; Robert D Steiner; Dorothy K Grange; Binyam Nardos; Robert C McKinstry; Desirée A White
Journal:  Neuropsychology       Date:  2009-01       Impact factor: 3.295

Review 6.  The truth of treating patients with phenylketonuria after childhood: the need for a new guideline.

Authors:  F J van Spronsen; P Burgard
Journal:  J Inherit Metab Dis       Date:  2008-08-12       Impact factor: 4.982

7.  Short-term dietary interventions in children and adolescents with treated phenylketonuria: effects on neuropsychological outcome of a well-controlled population.

Authors:  S C J Huijbregts; L M J de Sonneville; R Licht; F J van Spronsen; J A Sergeant
Journal:  J Inherit Metab Dis       Date:  2002-10       Impact factor: 4.982

8.  Meta-analysis of neuropsychological symptoms of adolescents and adults with PKU.

Authors:  J J Moyle; A M Fox; M Arthur; M Bynevelt; J R Burnett
Journal:  Neuropsychol Rev       Date:  2007-04-05       Impact factor: 7.444

Review 9.  Phenylketonuria: a review of current and future treatments.

Authors:  Naz Al Hafid; John Christodoulou
Journal:  Transl Pediatr       Date:  2015-10

10.  Phenylketonuria: nutritional advances and challenges.

Authors:  Marcello Giovannini; Elvira Verduci; Elisabetta Salvatici; Sabrina Paci; Enrica Riva
Journal:  Nutr Metab (Lond)       Date:  2012-02-03       Impact factor: 4.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.